Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 9/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867356 | 0.81 | NAAA (0.53) | NAAACTSLEPHX1ALDH1A1GAA | |
| SCHEMBL7423681 | 0.81 | NAAA (0.54) | NAAAIDO1TDO2CTSLALDH1A1 | |
| SCHEMBL4802366 | 0.81 | NAAA (0.52) | NAAAIDO1TDO2CTSLALDH1A1 | |
| SCHEMBL5105468 | 0.80 | NAAA (0.52) | NAAAIDO1TDO2CTSLEPHX1 | |
| SCHEMBL4871439 | 0.78 | NAAA (0.43) | NAAACTSLEPHX1ALDH1A1 | |
| SCHEMBL5180974 | 0.76 | NAAA (0.58) | NAAACTSLALDH1A1GAAASAH1 | |
| SCHEMBL765661 | 0.76 | NAAA (0.58) | NAAACTSLALDH1A1GAAASAH1 | |
| SCHEMBL3930648 | 0.76 | NAAA (0.58) | NAAACTSLALDH1A1GAAASAH1 | |
| SCHEMBL9197959 | 0.75 | NAAA (0.44) | NAAAIDO1TDO2CTSLALDH1A1 | |
| SCHEMBL17321317 | 0.75 | NAAA (0.52) | NAAAIDO1TDO2CTSLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2006076597-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NAAA 240/4885IDO1 2322/4885TDO2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.